A biologically active lipid, sphingosine-1-phosphate (S1P) is highly abundant in blood, and plays an important role in regulating the growth, survival, and migration of many cells. response was markedly suppressed by S1P 2 receptor antagonist JTE013, S1P 3 receptor antagonist CAY10444, or non-selective TRPC channel inhibitor Pyr2. Additionally, S1P increased chemokine CXCL1 mRNA expression and release, which were suppressed by TRPC inhibitor, inhibition of Ca 21 mobilization, MAPK pathway inhibitors, or knockdown of the TRPC channel isoform TRPC6.
migration of mammalian cells (Brinkmann, 2007; Pyne & Pyne, 2010) .
In astrocytes, S1P induces cellular proliferation (Malchinkhuu et al., 2003) , morphological changes (Rouach et al., 2006) , and cellular migration (Fischer et al., 2011) . Moreover, S1P induces expression of a variety of neurotrophic factors, such as GDNF (Yamagata et al., 2003) , NGF (Furukawa et al., 2007) and cytokines, such as interleukin (IL) 1b and CCL2 (Zhou & Murthy, 2004) in astrocytes. Moreover, S1P activates the G q/11 inositol lipid/Ca 21 signaling pathway in cortical astrocytes (Sorensen et al., 2003) . However, the precise molecular mechanisms underlying S1P-induced Ca 21 responses and functional changes in astrocytes remain unknown. Thus, we focused on and investigated the involvement of TRPC channels in S1P-induced functions in primary cultured astrocytes. To examine the role of TRPC channels in S1P-induced astrocytic responses, we examined Ca 21 responses, morphological changes, migration, and cytokine release.
Here, we provide the first indication of the possibility that TRPC6 channels are involved in S1P-induced Ca 21 responses and CXCL1 release.
| MATERIALS A ND METHODS

| Cultured Rat Cortical Astrocyte
All experiments were conducted in accordance with the ethical guidelines of the Kyoto University Animal Research Committee. Primary astrocyte-enriched cultures were prepared from cerebral cortices of 0-2 day-old postnatal Wistar/ST rats (Japan SLC, Hamamatsu, Japan), as previously described (Shirakawa et al., 2010) with slight modification.
Cells were dissociated with 3 mg/ml dispase (Gibco, Tokyo, Japan), and were plated in 75 cm 2 bent-cap flasks with 7 ml of Eagle's Minimum Essential Medium (EMEM; Nissui Pharmaceutical, Tokyo, Japan) containing 10% heat-inactivated fetal bovine serum (FBS; JRH Biosciences, Lenexa) in an incubator with 5% CO 2 at 378C. After cultivation for 2-4 weeks, the flasks were shaken on an orbital shaker at 250 rpm for 14-17 hr at 378C to remove microglia and oligodendrocytes. The remaining astrocytes were detached with 0.25% trypsin (Gibco), resuspended in fresh medium, and reseeded on 10 mm glass coverslips, 35 mm dishes or 48 well plates at a density of 2.5 3 10 4 cells/cm 2 . Cells were used at least 4-5 days before being used for experiments. Unless otherwise noted, all experiments were performed under serum starvation.
| Reverse Transcription (RT)-PCR
Total RNA was extracted from astrocytes in a 35-mm dish using a Nucleo Spin® RNA kit (TaKaRa Bio, Shiga, Japan). Using 1 lg of total RNA, two-step reverse transcription (RT)-PCR was performed with the ReverTra Ace® RT-PCR Kit (Toyobo, Osaka, Japan) using a PCR Thermal Cycler Dice® Gradient (Takara Bio; TP600). The pairs of primers used for amplification were 5 0 -GAAGTTCCACCGGCCCATGT-3 0 and 5 0 -GGAGATGTTCTTGCGGAAGG-3 0 for S1P receptor 1 (S1P 1 ); 5 0 -GTCTGGACCATCTGGAGGCT-3 0 and 5 0 -GTCTGAGGACCAGCAACGT C-3 0 for S1P receptor 2 (S1P 2 ); 5 0 -GACGCCAACAAGAAGCACCG-3 0 and 5 0 -GCTGATGAGAAAGGCAATGTA-3 0 for S1P receptor 3 (S1P 3 ); ] i ) was monitored using the fluorescent calcium indicator fura 2-AM (Dojindo, Kumamoto, Japan), as previously described (Miyake, Shirakawa, Nakagawa, & Kaneko, 2015) .
Astrocytes were cultured on 10 mm glass coverslips and grown for 4-5 days. For dye loading, the cells on a coverslip were loaded for 30 min with 5 lM fura 2-AM in Krebs-Ringer solution (140 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , 2 mM CaCl 2 , 10 mM glucose, and 10 mM HEPES) containing 0.01% cremophor EL (Sigma-Aldrich). Cells were washed with Krebs-Ringer solution and set on an imaging chamber. For the Ca 21 -free experiments, CaCl 2 was omitted, and 0.5 mM EGTA was added to the external solution. Loaded cells were transferred into a perfusion chamber with fresh buffer and mounted on a Nikon fluorescent microscope equipped with an AQUACOSMOS/ORCA-AG imaging system (Hamamatsu Photonics, Shizuoka, Japan). Fluorescent images were scanned at 500 nm and 2 s intervals, with alternate excitation at 340 and 380 nm at room temperature. The fluorescence ratio of individual cells is designated F340/380. Each experiment was repeated more than three times.
| Quantitative RT-PCR
After RT of total mRNA to cDNA using ReverTra Ace® qPCR RT Mas- 
| Western Blotting
Western blotting was performed as described previously (Shirakawa et al., 2010) , with slight modification. The drugs-treated cells were collected by a brief centrifugation and were lysed in RIPA buffer (Nacalai tesque, Kyoto, Japan) supplemented with phosphatase inhibitor cocktail 2 and 3 (P5726 and P0044, Sigma Aldrich). Proteins were diluted in NuPAGE® 4x LDS sample buffer (Life Technologies, Carlsbad CA), loaded onto a 10% SDS-polyacrylamide gel, and blotted onto Immobilon-P PVDF transfer membranes (Millipore, Bedford, MA). After a blocking step using Blocking One-P (Nacalai tesque), the membranes were incubated overnight at 48C with primary antibodies, which were all purchased from Cell Signaling Technologies, (Beverly, MA) diluted 1:1000 in Tris-buffered saline containing 0.1% Tween-20 and 10%
Blocking One-P. Phosphorylated proteins were detected using rabbit monoclonal or polyclonal antibodies against phospho-p44/42 MAPK (Erk1/2) (#9101), phospho-SAPK/JNK (#4671) and phospho-p38 MAPK (#9211) followed by incubation with peroxidase-conjugated donkey anti-rabbit IgG (1:5000 dilution; GE Healthcare, Little Chalfont, UK) for 1 hr at RT. Specific bands were detected by Immobilon Western Chemiluminescent HRP substrate (Millipore) and visualized using the ChemiImager 4400 imaging system (Alpha Innotech, San Leandro, CA). To normalize for total protein loading, blots were stripped and reprobed with rabbit polyclonal antibodies against SAPK/JNK (#9252), p44/42 MAPK (Erk1/2) (#9102), or p38 MAPK (#9212) followed by the same procedure as described above. The bands were densitometrically quantified using ImageJ software.
| TRPC6 siRNA Transfection
TRPC6-specific siRNA was used to block TRPC6-mediated signaling. 
Astrocytes were transfected with Stealth
| Fluorescence Staining
S1P-induced morphological changes were detected by actin staining, as previously described (Miyanohara, Shirakawa, Sanpei, Nakagawa, & Kaneko, 2015; Shirakawa et al., 2010) . After pre-treatment with serum-free EMEM for 10 min, cells on 10 mm glass coverslips (Matsunami Glass, Osaka, Japan) were treated with the drug of interest for 3
hr. Following fixation with 4% para-formaldehyde, the cells were soaked in 0.2% Tri-ton-X100 for permeabilization, and then incubated for 1 hr at 48C with rabbit Alexa Fluor488-conjugated phalloidin (1:40 dilution; Invitrogen, Carlsbad, CA) to visualize the actin cytoskeleton.
Before observation with a fluorescence microscope, 0.01 mg/ml
Hoechst 33342 was added to the cells on the glass for nuclear staining.
Astrocyte were defined as "polygonal cells" in the morphology if they exhibit polygonal shapes with an increase in their F-actin content adjacent to the cell membrane and do not display multipolar shapes with diffuse F-actin extending short protrusions, which were commonly observed in control treatment under serum starvation. Morphological changes were calculated as the percentage of polygonal-shaped astrocytes to the total number of Hoechst-positive cells.
| Scratch-Wound Assay
After enrichment of the cortical astrocytes, the cells were reseeded on 35 mm dishes and cultured for 1-2 weeks. Following serum starvation for 24 hr, the medium was removed, and a reference line was drawn. A scratch was made in the astrocyte monolayer with a 1-ml pipette tip along the reference line, creating 4-8 scratched areas. Cells were washed twice with phosphate-buffered saline to remove cell debris, and fresh serum-free media containing the drugs of interest were added. Images were taken at 0 and 72 hr, with the same field recorded in each case. To determine the area of migration, the leading edge of the scratched cells at 0 hr was superimposed onto the image taken at 72 hr. After treatments, measurements from 4 to 8 areas were averaged to determine the area of migration.
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| Statistical Analysis
Data were expressed as means 6 S.E.M. The statistical significance of the differences among groups was determined by a one-way analysis of variance (ANOVA) followed by Tukey's multiple comparison tests using GraphPad Prism 5 (GraphPad Software, La Jolla, CA) and a p value of less than 5% was considered significant.
| R E S U LTS
3.1 | S1P Receptors S1P 1 , S1P 2 , and S1P 3 are Expressed in Primary Rat Cortical Astrocytes S1P receptors are a family of G protein-coupled receptors (GPCRs), consisting of five members called S1P 1 , S1P 2 , S1P 3 , S1P 4 , and S1P 5 (Brinkmann, 2007; Pyne & Pyne, 2010) . First, we investigated the expression of the S1P receptor subtypes in cultured rat primary cortical astrocytes. RT-PCR analysis of mRNA extracted from cultured astrocytes detected the expression of S1P 1 , S1P 2 , and S1P 3 but not S1P 4
and S1P 5 (Fig. 1A ).
| S1P Induces Ca 21 Mobilization in Cultured
Cortical Astrocytes via G q -Coupled Receptors S1P 2 and S1P 3 S1P stimulates the G q/11 -inositol lipid/Ca 21 signaling pathway in cortical astrocytes (Sorensen et al., 2003 Representative traces and quantitative data of peak Ca 21 amplitude and sustained Ca 21 concentration due to S1P (1 lM)-induced Ca 21 mobilization after treatment with selective S1P 2 inhibitor JTE013 (1 lM) (G), selective S1P 3 inhibitor CAY10444 (10 lM) (H), PLC inhibitor U73122 (1 lM) (I), or G bg subunit activity inhibitor gallein (10 lM) (J). *P < 0.05, **p < 0.01 vs. S1P alone (n 5 6-16 (Fig. 1F) . Next, we examined whether Ca 21 responses are suppressed by either an inhibitor of G q -coupled receptor S1P 2 or S1P 3 . A selective S1P 2 inhibitor JTE013 (1 lM) significantly but partially suppressed both the peak amplitude and the sustained increase of [Ca 21 ] i (Fig. 1G) , and a selective S1P 3 inhibitor CAY10444 (10 lM) had a tendency to suppress peak amplitude and significantly but partially suppressed the sustained Ca 21 response (Fig. 1H ). In addition, PLC inhibitor U73122 (1 lM)
completely inhibited the S1P-induced Ca 21 elevation (Fig. 1I) , while the G bg subunit activity inhibitor gallein (10 lM) had no effect on the Ca 21 responses (Fig. 1J) (Grimaldi, 2006) . We investigated the expression of TRPC channels by RT-PCR analysis and detected specific high-intensity bands for TRPC1, C4, and C6 and a relatively low-intensity band for TRPC3 and C5 (Fig. 2D) . We investigated the involvement of TRPC channels in S1P-induced Ca 21 responses.
Application of the non-selective TRPC inhibitor Pyr2 significantly inhibited the peak amplitude and sustained increase in [Ca 21 ] i (Fig. 2E) . On the other hand, the selective TRPC3 inhibitor Pyr3 did not affect the 
lM) (C). (D) RT-PCR analysis of TRPC channels in primary rat cortical astrocytes. (E, F)
Astrocytes were treated with non-selective TRPC inhibitor Pyr2 (10 lM) (E) or selective TRPC3 inhibitor Pyr3 (3 lM) (F). *p < 0.05, **p < 0.01 vs. S1P alone (n 5 3-13)
| 1009 S1P-induced sustained increase in [Ca 21 ] i , while it significantly, albeit weakly, suppressed the peak amplitude (Fig. 2F ), indicating that TRPC6 is involved in both S1P-induced peak amplitude and sustained increase in [Ca 21 ] i .
| S1P-Induced Morphological Change is
Independent of Ca 21 Signaling Mediated by TRPC Channels S1P rearranges the actin cytoskeleton, leading to changes in astrocytic morphology (Rouach et al., 2006) . Staining with fluorescenceconjugated phalloidin revealed that continuous application of S1P (1 lM) for 3 hr caused actin cytoskeletal rearrangements and retraction of the protrusions in serum-starved astrocytes, most of which exhibited a typical polygonal shape (Fig. 3) . BAPTA-AM (3 lM), Pyr2 (10 lM), and Pyr3 (10 lM) all failed to inhibit this S1P-induced actin rearrangement with a polygonal morphology and cells treated with these reagents looked similar to those exposed to S1P (Fig. 3) , indicating that S1P-induced morphological change is independent of TRPC activation in astrocytes.
| S1P-Induced Astrocytic Migration is Independent of TRPC Channel-Mediated Ca 21
Signaling S1P promotes cellular migration in rat cortical astrocytes . Next, using a scratch-wound assay on a monolayer of pure astrocytes, we examined the effects of Pyr2 or Pyr3 on astrocytic migration and found that S1P significantly increased astrocytic migration and that neither Pyr2 (10 lM) nor Pyr3 (10 lM) affects S1P-induced astrocytic migration (Fig. 4) , suggesting that S1P-induced migration is independent of TRPC activation in astrocytes.
3.6 | S1P Increases CXCL1 Expression and Release from Astrocytes via G q -Coupled Receptors S1P 2 and S1P 3
Physiologically or abnormally activated astrocytes may produce and release some cytokines, inflammatory factors, and neurotrophic factors (Allaman, B elanger, & Magistretti, 2011; Verkhratsky et al., 2016) . Additionally, S1P-treated astrocytes release GDNF (Yamagata et al., 2003) , NGF (Furukawa et al., 2007) , Il1b, and CCL2 (Zhou & Murthy, 2004) .
Therefore, we investigated changes in the expression level of various factors 24 hr after treatment with 1 lM S1P. Among tested genes, we found that the mRNA for only CXCL1, one of the CXC chemokines, was significantly upregulated in S1P-treated astrocytes ( Fig. 5A-H) .
Using ELISA assay, we measured the content of CXCL1 in the culture medium of astrocytes treated with S1P (1 lM) after 24 hr and found that S1P increased the CXCL1 release, which was significantly inhibited by the S1P 2 receptor inhibitor JTE013 at 1 lM and the S1P 3 receptor inhibitor CAY10444 at 10 lM, but not the S1P 1 receptor inhibitor VPC44116 at 1 lM (Fig. 5I) . These findings indicate that S1P increased CXCL1 production and release via G q -coupled receptors S1P 2 and S1P 3 in astrocytes (Fig. 5I ).
3.7 | S1P-Induced CXCL1 Release is Mediated by TRPC6, Ca 21 Signaling, and the MAPK Pathway
Finally, we investigated the mechanisms underlying S1P-induced CXCL1 release. Mitogen-activated protein kinases (MAPKs), a family of serine/threonine kinases, link receptor activation in the cell membrane to gene expression in the nucleus (Chang & Karin, 2001 ). We examined the phosphorylation levels of MAPKs, such as ERK, JNK, and p38, in the presence and absence of S1P and found that phosphorylation levels of all MAPKs significantly increased in S1P-stimulated astrocytes FIG URE 3 S1P-induced morphological changes in cultured rat astrocytes. Representative photographs were obtained from serumstarved rat cortical astrocytes that received control treatment (A), S1P at 1 lM (B), S1P and BAPTA-AM at 3 lM (C), S1P and Pyr2 at 10 lM (D), or S1P and Pyr3 at 10 lM (E) for 3 hr. The actin cytoskeleton was detected by phalloidin staining, shown in green fluorescence. Cellular nuclei were stained with Hoechst 33342, as shown in blue fluorescence. Scale bar, 50 lm. Note that cultured astrocytes display process-bearing stellate cells under serum starvation, and change into polygonal morphology in response to S1P. (F) Quantification of the percentage of polygonal cells in the presence or absence of the indicated drugs. ***p < 0.001 vs. control (n 5 3-5) [Color figure can be viewed at wileyonlinelibrary.com] (Fig. 6A) . Moreover, S1P-induced CXCL1 release was significantly inhibited by MEK inhibitor PD98059 (30 mM), JNK inhibitor SP600125
(SP) (30 mM), or p38 inhibitor SB203580 (SB) (30 mM) (Fig. 6B) . The non-selective TRPC channel inhibitor Pyr2 (1-10 mM), but not the selective TRPC3 inhibitor Pyr3, significantly inhibited the increase in CXCL1 release (Fig. 6C, D found that all the drugs significantly blocked S1P-induced CXCL1 release (Fig. 6E) . Collectively, these results suggest that S1P induces Ca 21 entry through TRPC channels, which could activate MAPK signaling and result in an increase in CXCL1 release.
Among the TRPC channels, TRPC1, 4, and 6 were abundantly expressed in our astrocyte preparation, and, since TRPC1 and TRPC4
themselves do not form a functional channel (Birnbaumer, 2009; Kiyonaka et al., 2009) . We focused on the role of TRPC6 in mediating S1P-induced CXCL1 release. We developed a specific siRNA for TRPC6 (si-TRPC6) and found that it reduced the mRNA levels of TRPC6 by more than 50% (Fig. 6F) . Subsequently, we confirmed selective TRPC6 knockdown using the DAG analogue OAG, which is a direct activator of TRPC3, 6, and 7. The percentage of cultured astrocytes responding to OAG was also significantly reduced by si-TRPC6 treatment (Fig. 6G-I ), indicating that TRPC6 function was partially and significantly suppressed with si-TRPC6 treatment. On the other hand, treatment with OAG at ranging from 1 to100 lM did not induce CXCL1 release (Fig.   6J ), suggesting that OAG alone can induce astrocytic Ca 21 responses, but does not mimic S1P-induced CXCL1 release. Moreover, we examined the response to S1P in TRPC6 downregulated astrocytes and found that S1P-induced sustained increase, but not the peak amplitude, in [Ca 21 ] i was significantly inhibited by downregulation of TRPC6 with si-TRPC6 (Fig. 3K-N) . Subsequently, we examined the effects of RNAimediated knockdown of TRPC6 on CXCL1 release. After 24 hr of treatment with S1P, si-TRPC6 significantly inhibited S1P-induced CXCL1 release (Fig. 6O) , demonstrating that TRPC6 contributes to S1P-induced Ca 21 responses and CXCL1 release.
FIG URE 4 S1P-induced astrocytic migration in cultured rat astrocytes. Astrocytic migration was measured by scratch-wound assay. Astrocytes were treated with FBS (0%) (control) or the indicated drugs for 72 hr following serum starvation. Representative photographs were obtained at 0 and 72 hr. The areas of astrocytic migration were normalized to that of the control cells grown in EMEM containing FBS (10%) for 72 hr. The depicted area of migration is representative of three independent experiments performed in 4-8 wells in one experiment. Scale bar, 100 lm
| DISCUSSION
In this study, we investigated S1P-induced Ca 21 responses and CXCL1 release and found that S1P induced stimulation of G q -coupled receptors S1P 2 and S1P 3 following Ca 21 influx via TRPC6, which resulted in activation of the MAPK pathway and CXCL1 release. (Sorensen et al., 2003) , and migration via S1P 1 , Ca 21 signaling may not be important in these cellular responses. On the other hand, we previously reported that a thrombin receptor proteinase-activated receptor 1 (PAR1), coupled with G q/11 , G 12/13 , and G i/o , induces proliferation and morphological changes that are mediated by Ca 21 signaling via TRPC3 (Shirakawa et al., 2010 Changes in mRNA expression levels and CXCL1 release into astrocyte culture medium 24 hr after S1P treatment. (A-H) mRNA levels of BDNF (A), GDNF (B), NGF (C), COX2 (D), ICAM1 (E), IL6 (F), CCL5 (G), and CXCL1 (H) in rat primary astrocytes that received control treatment or S1P (1 lM) for 24 hr. *p < 0.05 vs. control (n 5 4-7). (I) CXCL1 release in the astrocyte culture medium was measured by ELISA assay. Astrocytes were treated with control media, S1P (1 lM), S1P and S1P 1 antagonist VPC44116 (VPC; 1 lM), S1P and S1P 2 antagonist JTE013 (JTE; 1 lM), or S1P and S1P 3 antagonist CAY10444 (CAY; 10 lM). *p < 0.05, ***p < 0.001 vs. control, ###p < 0.001 vs. S1P alone (n 5 4)
FIG URE 6 Involvement of TRPC6, Ca 21 signaling, and the MAPK pathways in S1P-induced CXCL1 release. (A) S1P-induced activation of MAPK pathways. Astrocytes were treated with control media or 1 lM S1P for 10 min (p38) or 30 min (ERK, JNK). Cell lysates were immunoblotted for phosphorylated MAPK proteins (p-ERK, p-JNK, p-p38) or total MAPK proteins (t-ERK, t-JNK, t-p38). Each value is expressed as the ratio of the phosphorylated MAPK protein level to the corresponding total MAPK protein level and the control value was set to 1. *p < 0.05 vs. control (n 5 3-5). (B-E, J,O) Astrocytes were treated with control media, S1P (1 lM), S1P and MEK inhibitor PD98059 (PD; 30 lM), JNK inhibitor SP600125 (SP; 30 lM), or p38 inhibitor SB203580 (SB; 30 lM) (B), S1P and Pyr2 (1-10 lM) (C), S1P and Pyr3 (1-10 lM) (D), S1P and PKC inhibitor bisindolylmaleimide I (BIM; 1 lM), endoplasmic reticulum Ca 21 -ATPase inhibitor CPA (30 lM), or intracellular Ca 21 chelator BAPTA-AM (3 lM) (E), or OAG (1-100 lM) (J). CXCL1 release in the astrocyte culture medium was measured by ELISA assay. ***p < 0.001 vs. control, #p < 0.05, ###p < 0.001 vs. S1P alone (n 5 4-5). Mazzocco-Spezzia, Pulina, & Golovina, 2007 Sphingosine kinase, which can phosphorylate sphingosine to produce S1P, is highly expressed in the brain (Fukuda, Kihara, & Igarashi, 2003) , and the S1P receptors (S1P [1] [2] [3] [4] [5] ) that belong to the GPCR super family are also expressed in brain cells, including astrocytes (Groves, Kihara, & Chun, 2013) . There have been some reports indicating that S1P induces the expression of some neurotrophic factors including GDNF (Yamagata et al., 2003) and NGF (Furukawa et al., 2007) in cultured astrocytes, which were not consistent with our observations that rat cultured rat astrocytes did not show any change in GDNF and NGF mRNA levels by S1P treatment for 24 hr.
Since the previous studies demonstrate that S1P-induced increase in the mRNA expression levels of NGF as well as GDNF can peak at 6-12 hr, gradually decline to control level by 24 hr, further time-course study will be needed to address the discrepancy in the responses to S1P.
Conversely, S1P can be involved in neuroinflammatory diseases in various pathological conditions. For example, the concentration of S1P in the brain increases after ischemia in a mouse thrombosis model of the middle cerebral artery (Kimura et al., 2008) , and S1P production is facilitated in reactive astrocytes and activated microglia (Kimura et al., 2007) . Also, in the cerebrospinal fluid of multiple sclerosis (MS) patients, the S1P concentration (Kułakowska et al., 2010) and S1P 1 and S1P 3 are upregulated in MS lesions (Van Doorn et al., 2010) . Since S1P concentrations are high in blood but low in tissues (Obinata & Hla, 2012) , S1P can leak and affect the CNS environment when the bloodbrain barrier becomes permeable in some pathological conditions.
In this study, S1P promoted CXCL1 release after G q -coupled receptor stimulation. Stimulation of other G q -coupled receptors results in an increase in CXCL1 production or secretion. For example, thrombin or agonist of PAR1 induced CXCL1 release from astrocytes via Ca 21 signaling (Wang, Luo, & Reiser, 2007) . Activation of endothelin B receptor also promotes CXCL1 production mediated by the NF-jB pathway (Koyama et al., 2013) . Although IL1b (An, Chen, & Quan, 2011) , in astrocytes. Treatment with a neutralizing antibody for CXCL1 or an antagonist for CXCR1/2, a receptor of CXCL1, improves neurological symptoms in murine models of inflammatory pain (Cao et al., 2014) , cerebral ischemia (Garau et al., 2006) , spinal cord injury (Gorio et al., 2007) , and cerebral hemorrhage (Matsushita et al., 2014) . Since S1P is upregulated in these diseases (Obinata & Hla, 2012) , so it is conceivable that an increase in CXCL1 production in astrocytes is involved in exacerbation of inflammation in these neuroinflammatory diseases.
Meanwhile, CXCL1 also has beneficial effects by promoting oligodendrocyte progenitor proliferation (Wu et al., 2000) , and controlling positioning of oligodendrocyte precursors (Tsai et al., 2002) . In MS mouse models, studies report conflicting results showing that CXCL1 is either proinflammatory or neuroprotective (Omari, John, Lango, & Raine, 2006) . Therefore, whether CXCL1 from astrocytes promotes neuroinflammation or has a beneficial effect may depend on each pathological condition and disease stage.
In conclusion, this study demonstrated that S1P induces Ca 21 influxes via TRPC6, which activates the MAPK pathway to promote CXCL1 release. Since S1P is upregulated in inflammatory diseases, S1P-induced CXCL1 release may be important in inhibiting CNS inflammation, in which excessive astrocytic activation plays a role.
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